AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
Lantheus Holdings, Inc.
Video analysis: LNTH
All videosNo video analysis for this stock yet. Request one from our team.
News: LNTH
Are LNTH, ITGR, CZR Obtaining Fair Deals for their Shareholders?
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws
Lantheus Holdings Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Lantheus Holdings, Inc. - LNTH
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Lantheus Holdings, Inc. (NasdaqGM: LNTH) to Curium US Holdings LLC. Under the terms of the proposed transaction, shareholders of Lantheus will receive $102.50 per share in cash, plus non-transferable Contingent Value Rights providing for up to $12.00 per share in potential additional cash payments,.
LNTH Stock Alert: Halper Sadeh LLC is Investigating Whether Lantheus Holdings, Inc. is Obtaining a Fair Price for its Shareholders
Halper Sadeh LLC, an investor rights law firm, is investigating the sale of Lantheus Holdings, Inc. (NASDAQ: LNTH) to Curium US Holdings LLC for $102.50 per sha
LNTH Stock Alert: Halper Sadeh LLC is Investigating Whether Lantheus Holdings, Inc. is Obtaining a Fair Price for its Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the sale of Lantheus Holdings, Inc. (NASDAQ: LNTH) to Curium US Holdings LLC for $102.50 per share in cash, plus non-transferable Contingent Value Rights providing for up to $12.00 per share in potential additional cash payments, subject to achievement of specified commercial milestones for Lantheus' products through 2030.Halper Sadeh encourages Lantheus shareholders to click here to learn more about their.
US FDA approves Lantheus' brain-imaging agent for Alzheimer's assessment
The U.S. Food and Drug Administration has approved a radioactive agent from Lantheus Holdings for use in brain scans to help assess patients for Alzheimer's disease, the company said on Friday.
Lantheus Announces FDA Approval of TAUKLARIFY™ (Florquinitau F 18 Injection), an F18-Labeled Tau PET Imaging Agent for Alzheimer's Disease
BEDFORD, Mass., Aug. 14, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus” or the “Company”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced U.S. Food and Drug Administration (FDA) approval of TAUKLARIFY™ (florquinitau F 18 injection), also referred to as MK-6240, a radiodiagnostic agent indicated for positron emission tomography (PET) of the brain in adults with cognitive impairment who are being evaluated for Alzheimer's disease to identify patients with tau neurofibrillary tangle (NFT) pathology. TAUKLARIFY has a limitation of use. The safety and effectiveness of TAUKLARIFY have not been established for the evaluation of non-Alzheimer's disease tauopathies.
Are DSGR, LNTH, ATKR Obtaining Fair Deals for their Shareholders?
Are DSGR, LNTH, ATKR Obtaining Fair Deals for their Shareholders? PR Newswire NEW YORK, Aug. 7, 2026
Are DSGR, LNTH, ATKR Obtaining Fair Deals for their Shareholders?
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws
Similar companies
-
Indivior Pharmaceuticals Inc
INDV
·
NASDAQ
Compare
-
ACADIA Pharmaceuticals Inc.
ACAD
·
NASDAQ
Compare
-
Amneal Pharmaceuticals, Inc.
AMRX
·
NASDAQ
Compare
-
ADMA Biologics, Inc.
ADMA
·
NASDAQ
Compare
-
Supernus Pharmaceuticals, Inc.
SUPN
·
NASDAQ
Compare
-
Praxis Precision Medicines, Inc.
PRAX
·
NASDAQ
Compare